Talimogene laherparepvec, often referred to as T-VEC, is an advanced form of cancer immunotherapy. It is a genetically modified version of the herpes simplex virus type 1 (HSV-1), designed to selectively infect and kill cancer cells. The virus is engineered to produce a protein called granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates the body's immune system to attack the tumor.
